Editas, Press Release

ir.editasmedicine.com

CAMBRIDGE, Mass., Dec. 19, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced it has exclusively licensed intellectual property related to new CRISPR technologies for human therapeutics that will enhance and broaden the range of medicines the Company can develop.

Read more...
Linkedin

Want to receive more content like this in your inbox?